Beykoz Institute of Life Sciences and Biotechnology, Bezmialem Vakif University, 34820 Istanbul, Turkey.
Department of Infectious Diseases and Clinical Microbiology, Medical School, Bezmialem Vakif University, 34093 Istanbul, Turkey; and.
J Immunol. 2020 Nov 15;205(10):2719-2725. doi: 10.4049/jimmunol.2000840. Epub 2020 Sep 25.
The recent pandemic of COVID-19 has caused a tremendous alarm around the world. Details of the infection process in the host have significant bearings on both recovery from the disease and on the correlates of the protection from the future exposures. One of these factors is the presence and titers of neutralizing Abs (NAbs) in infected people. In the current study, we set out to investigate NAbs in the recovered subjects discharged from the hospital in full health. Serum samples from a total of 49 documented consecutive COVID-19 subjects were included in the study. All the subjects were adults, and serum samples collected during the discharge were tested in viral neutralization, enzyme immunoassay (EIA), and Western immunoblot tests against viral Ags. Even though a majority of the recovered subjects had raised significant NAb titers, there is a substantial number of recovered patients (10 out of 49) with no or low titers of NAbs against the virus. In these cohorts as well as in patients with high NAb titers, viral Ag binding Abs were detectable in EIA tests. Both NAb titers and EIA detectable Abs are increased in patients experiencing a severe form of the disease, and in older patients the Ab titers were heightened. The main conclusion is that the recovery from SARS-CoV-2 infection is not solely dependent on high NAb titers in affected subjects, and this recovery process is probably produced by a complex interplay between many factors, including immune response, age of the subjects, and viral pathology.
最近的 COVID-19 大流行在全球范围内引起了极大的恐慌。宿主感染过程的细节对疾病的康复以及对未来暴露的保护相关性都有重要影响。其中一个因素是感染人群中中和抗体(NAb)的存在和滴度。在本研究中,我们着手研究从医院完全康复出院的患者体内的 NAb。共纳入了 49 名有记录的连续 COVID-19 患者的血清样本。所有患者均为成年人,出院时采集的血清样本用于病毒中和试验、酶联免疫吸附试验(EIA)和 Western 免疫印迹试验检测病毒抗原。尽管大多数康复患者都产生了高滴度的 NAb,但仍有相当数量的康复患者(49 例中有 10 例)对病毒的 NAb 滴度较低或无反应。在这些队列以及 NAb 滴度高的患者中,EIA 试验中可检测到病毒 Ag 结合 Ab。患有严重疾病的患者 NAb 滴度和 EIA 可检测 Ab 均升高,老年患者的 Ab 滴度升高。主要结论是,SARS-CoV-2 感染的康复不仅仅依赖于受影响患者体内的高 NAb 滴度,而且这种康复过程可能是由许多因素的复杂相互作用产生的,包括免疫反应、患者年龄和病毒病理学。